Liver-targeted doxorubicin: Effects on rat regenerating hepatocytes

Liver International

Volumn 24, Issue 3, 2004, Pages 246-252

  Di Stefano, Giuseppina ^a   Derenzini, Massimo ^a   Kratz, Felix ^b   Lanza, Marcella ^a   Fiume, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Doxorubicin; Hepatocarcinoma chemotherapy; Liver regeneration; Liver targeting

Indexed keywords

ALANINE AMINOTRANSFERASE; ASIALOGLYCOPROTEIN RECEPTOR; DAUNORUBICIN; DNA; DOXORUBICIN; DOXORUBICIN DERIVATIVE; HUMAN ALBUMIN; SODIUM CHLORIDE; TRITIUM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG TARGETING; DRUG TISSUE LEVEL; LIVER CELL CARCINOMA; LIVER REGENERATION; LIVER RESECTION; MALE; MITOSIS INDEX; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 3142705894     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0916.x     Document Type: Article

References (32)

1. Morell A G, Irvine R A, Sternlieb I, Scheinberg I H, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 1968; 243: 155-9.
2. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-4.
3. Fiume L, Mattioli A, Balboni P G, Tognon M, Barbanti-Brodano G, de Vries J, et al. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 1979; 103: 47-51.
4. Fiume L, Busi C, Mattioli A, Barbanti-Brodano G. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 1981; 129: 261-4.
5. Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G, Faulstich H. Galactosylated poly(L-lysine) as a hepatotropic carrier of 9-β-D-arabinofuranosyladenine 5′ monophosphate. FEBS Lett 1986; 203: 203-6.
6. O'Hare K B, Hume I C, Scarlett L, Chytry V, Kopeckova P, Kopecek J, et al. Effect of galactose on interaction of N-(2-hydroxypropyl) metacrylamide copolymers with hepatoma cells in culture: preliminary applications to an anticancer agent, daunomycin. Hepatology 1989; 10: 207-14.
7. Bijsterbosch M K, van Berkel T J C. Native and modified lipoproteins as drug delivery systems. Adv Drug Del Rev 1990; 5: 231-51.
8. Jansen R W, Kruijt J, van Berkel T J C, Meijer D K F. Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to a specific uptake in rat and human hepatocytes. Hepatology 1993; 18: 146-52.
9. Fiume L, Cerenzia M R, Bonino F, Busi C, Mattioli A, Brunetto M R, et al. Inhibition Hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988; 2: 13-5.
10. Torrani Cerenzia M R, Fiume L, de Bernardi Venon W, Lavezzo B, Brunetto M R, Ponzetto A, et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects. Hepatology 1996; 23: 657-61.
11. Zarski J P, Barange K, Souvignet C, Bertini M, Marcellin P, Tran A, et al. Efficacy and safety of L-HSA-ara-AMP in chronic hepatitis B patients non responder to interferon therapy: a randomized clinical trial. J Hepatol 2001; 34: 486-8.
12. Hyodo I, Mizuno M, Yamada G, Tsuji T. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 1993; 13: 80-5.
13. Trerè D, Fiume L, Badiali de Giorgi L, di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 1999; 81: 404-8.
14. Schneider Y, Abarca J, Aboud-Pirak E, Baurain R, Ceulemans F, Deprez-de Campeneere D, et al. Drug targeting in human cancer chemotherapy. In: Gregoriadis G, Poste G, Senior J, Trouet A, eds. Receptor-mediated Targeting of Drugs, NATO ASI Series A: Life Sciences. New York: Plenum Press, 1984; 82, 1-25.
15. di Stefano G, Busi C, Derenzini M, Treré D, Fiume L. Conjugation of 5-fluoro-2′-deoxyuridine with lactosaminated poly-L-lysine to reduce extra-hepatic toxicity in the treatment of hepatocarcinoma. Ital J Gastroenterol Hepatol 1998; 30: 173-7.
16. di Stefano G, Kratz F, Lanza M, Fiume L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig Liver Dis 2003; 35: 428-33.
17. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969; 47: 223-58.
18. Leung T W T, Johnson P J. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28: 514-20.
19. Willner D, Trail P A, Hofstead S J, King H D, Lasch S J, Braslawsky G R, et al. (6-Maleinimidocaproyl)hydrazone derivative of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 1993; 4: 521-7.
20. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine ribonuclease A dimer. J Biol Chem 1978; 253: 2070-72.
21. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to the parent compound. J Med Chem 2002; 45: 5523-33.
22. Meunier L, Bourgerie S, Mayer R, Roche A C, Monsigny M. Optimized conditions to couple two water soluble biomolecules through alkylamine thiolation and thioetherification. Bioconjug Chem 1999; 10: 206-12.
23. Higgins G, Handerson R. Experimental pathology of the liver. 1. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931; 12: 186-202.
24. Bots A M, van Oort W J, Noordoek J, van Dijk A, Klein S W, van Hoesel Q G. Analysis of adriamycin and adriamycinol in micro volumes of rat plasma. J Chromatogr 1983; 272: 421-7.
25. Schneider W C, Greco A E. Incorporation of pyrimidine deoxyribonucleosides into liver lipids and other components.. Biochim Biophys Acta 1971; 228: 610-26.
26. Burton K. A study for the conditions and mechanisms of diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1956; 62: 315-23.
27. Calabresi P, Chabner B A. Chemotherpy of neoplastic diseases. In: Hardman J G, Limbard L E, Molinoff P B, Ruddon R W, Gilman A G, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: Mc Graw-Hill, 1996; 1225-87.
28. Merski J A, Daskal I, Busch H. Effects of adriamycin on ultrastructure of nucleoli in the heart and liver cells of the rat. Cancer Res 1976; 36: 1580-4.
29. Julyan P J, Seymour L W, Ferry D R, Daryani S, Boivin C M, Doran J, et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release 1999; 57: 281-90.
30. Hopewel J W, Duncan R, Wilding D, Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK 2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumor agent. Hum Exp Toxicol 2001; 20: 461-70.
31. Seymour L W. Soluble polymers for lectin-mediated drug targeting. Adv Drug Deliv Rev 1994; 14: 89-111.
32. Goddard P, Hutchinson L E, Brown J, Brookman L J. Soluble polymeric carriers for drug delivery. Part 2. Preparation and in vivo behaviour of N-acylethylenimine copolymers. J Control Release 1989; 10: 5-16.